Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Horizon Pharma, Inc. (HZNP) Inks Exclusive Agreement With Mundipharma To Commercialize LODOTRA In Middle East And Africa Regions

|Includes: Horizon Therapeutics Public Limited Company (HZNP)

Specialty pharmaceutical company Horizon Pharma announced that its Swiss subsidiary has signed an exclusive agreement with Mundipharma to commercialize and distribute LODOTRA in the Middle East and African regions.

LODOTRA is an innovative delayed-release formulation of prednisone that is designed specifically to deliver the active drug at the most physiologically efficient time. LODOTRA is approved in the United States under the trade name RAYOS and is approved in more than 30 other countries to treat moderate to severe rheumatoid arthritis (NYSE:RA) when accompanied by morning stiffness.

Bringing an important potential innovation in RA treatment to the Middle East and African regions, LODOTRA helps control numerous disease states that are characterized by excessive inflammation, including inflammation of the joints in arthritis. The drug also helps reduce the early morning joint pain and stiffness that are associated with RA, giving it the potential to greatly improve patients' quality of life.

"Mundipharma has a highly respected reputation through its product portfolio across multiple geographies, including LODOTRA in Europe, and we are pleased to expand our existing agreement with them to commercialize LODOTRA in these additional territories," said Horizon Pharma Executive Vice President and Chief Commercial Officer Todd N. Smith.

According to the terms of the agreement, Mundipharma will have commercialization rights for LODOTRA in 55 additional countries. The company will utilize a combination of company resources and partnerships to support LODOTRA commercialization in licensed regions.

For more information, visit

MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit